Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice

Taher Nassar, Serge Yarovoi, Rami Abu Fanne, Otailah Waked, Timothy C. Allen, Steven Idell, Douglas B. Cines, Abd Al Roof Higazi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The concentration of urokinase plasminogen activator (uPA) is elevated in pathological settings such as acute lung injury, where pulmonary arterial contractility and permeability are disrupted. uPA limits the accretion of fibrin after injury. Here we investigated whether uPA also regulates pulmonary arterial contractility and permeability. Contractility was measured using isolated pulmonary arterial rings. Pulmonary blood flow was measured in vivo by Doppler and pulmonary vascular permeability, according to the extravasation of Evans blue. Our data show that uPA regulates the in vitro pulmonary arterial contractility induced by phenylephrine in a dose-dependent manner through two receptor-dependent pathways, and regulates vascular contractility and permeability in vivo. Physiological concentrations of uPA (≤1 nM) stimulate the contractility of pulmonary arterial rings induced by phenylephrine through the low-density lipoprotein receptor-related protein receptor. The procontractile effect of uPA is independent of its catalytic activity. At pathophysiological concentrations, uPA (20 nM) inhibits contractility and increases vascular permeability. The inhibition of vascular contractility and increase of vascular permeability is mediated through a two-step process that involves docking to N-methyl-Daspartate receptor-1 (NMDA-R1) on pulmonary vascular smooth muscle cells, and requires catalytic activity. Peptides that specifically inhibit the docking of uPA to NMDA-R, or the uPA variant with a mutated receptor docking site, abolished both the effects of uPA on vascular contractility and permeability, without affecting its catalytic activity. These data show that uPA, at concentrations found under pathological conditions, reduces pulmonary arterial contractility and increases permeability though the activation of NMDA-R1. The selective inhibition of NMDAR-1 activation by uPA can be accomplished without a loss of fibrinolytic activity.

Original languageEnglish (US)
Pages (from-to)1015-1021
Number of pages7
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume45
Issue number5
DOIs
StatePublished - Nov 1 2011
Externally publishedYes

Fingerprint

Plasminogen Activators
Urokinase-Type Plasminogen Activator
Capillary Permeability
Lung
Permeability
Catalyst activity
Phenylephrine
Chemical activation
LDL-Receptor Related Proteins
Evans Blue
Acute Lung Injury
LDL Receptors
N-Methylaspartate
Fibrin
Vascular Smooth Muscle
Smooth Muscle Myocytes
Blood Vessels
Muscle
Blood
Cells

Keywords

  • Lung
  • NMDA-R
  • Permeability
  • Urokinase

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice. / Nassar, Taher; Yarovoi, Serge; Fanne, Rami Abu; Waked, Otailah; Allen, Timothy C.; Idell, Steven; Cines, Douglas B.; Higazi, Abd Al Roof.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 45, No. 5, 01.11.2011, p. 1015-1021.

Research output: Contribution to journalArticle

Nassar, Taher ; Yarovoi, Serge ; Fanne, Rami Abu ; Waked, Otailah ; Allen, Timothy C. ; Idell, Steven ; Cines, Douglas B. ; Higazi, Abd Al Roof. / Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice. In: American Journal of Respiratory Cell and Molecular Biology. 2011 ; Vol. 45, No. 5. pp. 1015-1021.
@article{dc3b7d4fd62840579e72d1a3bde7990f,
title = "Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice",
abstract = "The concentration of urokinase plasminogen activator (uPA) is elevated in pathological settings such as acute lung injury, where pulmonary arterial contractility and permeability are disrupted. uPA limits the accretion of fibrin after injury. Here we investigated whether uPA also regulates pulmonary arterial contractility and permeability. Contractility was measured using isolated pulmonary arterial rings. Pulmonary blood flow was measured in vivo by Doppler and pulmonary vascular permeability, according to the extravasation of Evans blue. Our data show that uPA regulates the in vitro pulmonary arterial contractility induced by phenylephrine in a dose-dependent manner through two receptor-dependent pathways, and regulates vascular contractility and permeability in vivo. Physiological concentrations of uPA (≤1 nM) stimulate the contractility of pulmonary arterial rings induced by phenylephrine through the low-density lipoprotein receptor-related protein receptor. The procontractile effect of uPA is independent of its catalytic activity. At pathophysiological concentrations, uPA (20 nM) inhibits contractility and increases vascular permeability. The inhibition of vascular contractility and increase of vascular permeability is mediated through a two-step process that involves docking to N-methyl-Daspartate receptor-1 (NMDA-R1) on pulmonary vascular smooth muscle cells, and requires catalytic activity. Peptides that specifically inhibit the docking of uPA to NMDA-R, or the uPA variant with a mutated receptor docking site, abolished both the effects of uPA on vascular contractility and permeability, without affecting its catalytic activity. These data show that uPA, at concentrations found under pathological conditions, reduces pulmonary arterial contractility and increases permeability though the activation of NMDA-R1. The selective inhibition of NMDAR-1 activation by uPA can be accomplished without a loss of fibrinolytic activity.",
keywords = "Lung, NMDA-R, Permeability, Urokinase",
author = "Taher Nassar and Serge Yarovoi and Fanne, {Rami Abu} and Otailah Waked and Allen, {Timothy C.} and Steven Idell and Cines, {Douglas B.} and Higazi, {Abd Al Roof}",
year = "2011",
month = "11",
day = "1",
doi = "10.1165/rcmb.2010-0302OC",
language = "English (US)",
volume = "45",
pages = "1015--1021",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice

AU - Nassar, Taher

AU - Yarovoi, Serge

AU - Fanne, Rami Abu

AU - Waked, Otailah

AU - Allen, Timothy C.

AU - Idell, Steven

AU - Cines, Douglas B.

AU - Higazi, Abd Al Roof

PY - 2011/11/1

Y1 - 2011/11/1

N2 - The concentration of urokinase plasminogen activator (uPA) is elevated in pathological settings such as acute lung injury, where pulmonary arterial contractility and permeability are disrupted. uPA limits the accretion of fibrin after injury. Here we investigated whether uPA also regulates pulmonary arterial contractility and permeability. Contractility was measured using isolated pulmonary arterial rings. Pulmonary blood flow was measured in vivo by Doppler and pulmonary vascular permeability, according to the extravasation of Evans blue. Our data show that uPA regulates the in vitro pulmonary arterial contractility induced by phenylephrine in a dose-dependent manner through two receptor-dependent pathways, and regulates vascular contractility and permeability in vivo. Physiological concentrations of uPA (≤1 nM) stimulate the contractility of pulmonary arterial rings induced by phenylephrine through the low-density lipoprotein receptor-related protein receptor. The procontractile effect of uPA is independent of its catalytic activity. At pathophysiological concentrations, uPA (20 nM) inhibits contractility and increases vascular permeability. The inhibition of vascular contractility and increase of vascular permeability is mediated through a two-step process that involves docking to N-methyl-Daspartate receptor-1 (NMDA-R1) on pulmonary vascular smooth muscle cells, and requires catalytic activity. Peptides that specifically inhibit the docking of uPA to NMDA-R, or the uPA variant with a mutated receptor docking site, abolished both the effects of uPA on vascular contractility and permeability, without affecting its catalytic activity. These data show that uPA, at concentrations found under pathological conditions, reduces pulmonary arterial contractility and increases permeability though the activation of NMDA-R1. The selective inhibition of NMDAR-1 activation by uPA can be accomplished without a loss of fibrinolytic activity.

AB - The concentration of urokinase plasminogen activator (uPA) is elevated in pathological settings such as acute lung injury, where pulmonary arterial contractility and permeability are disrupted. uPA limits the accretion of fibrin after injury. Here we investigated whether uPA also regulates pulmonary arterial contractility and permeability. Contractility was measured using isolated pulmonary arterial rings. Pulmonary blood flow was measured in vivo by Doppler and pulmonary vascular permeability, according to the extravasation of Evans blue. Our data show that uPA regulates the in vitro pulmonary arterial contractility induced by phenylephrine in a dose-dependent manner through two receptor-dependent pathways, and regulates vascular contractility and permeability in vivo. Physiological concentrations of uPA (≤1 nM) stimulate the contractility of pulmonary arterial rings induced by phenylephrine through the low-density lipoprotein receptor-related protein receptor. The procontractile effect of uPA is independent of its catalytic activity. At pathophysiological concentrations, uPA (20 nM) inhibits contractility and increases vascular permeability. The inhibition of vascular contractility and increase of vascular permeability is mediated through a two-step process that involves docking to N-methyl-Daspartate receptor-1 (NMDA-R1) on pulmonary vascular smooth muscle cells, and requires catalytic activity. Peptides that specifically inhibit the docking of uPA to NMDA-R, or the uPA variant with a mutated receptor docking site, abolished both the effects of uPA on vascular contractility and permeability, without affecting its catalytic activity. These data show that uPA, at concentrations found under pathological conditions, reduces pulmonary arterial contractility and increases permeability though the activation of NMDA-R1. The selective inhibition of NMDAR-1 activation by uPA can be accomplished without a loss of fibrinolytic activity.

KW - Lung

KW - NMDA-R

KW - Permeability

KW - Urokinase

UR - http://www.scopus.com/inward/record.url?scp=80555125051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80555125051&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2010-0302OC

DO - 10.1165/rcmb.2010-0302OC

M3 - Article

VL - 45

SP - 1015

EP - 1021

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 5

ER -